

Tempus Sequencing Laboratories

Tempus is CAP-accredited and licensed under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). It is authorized to provide diagnostic laboratory services in Illinois, Georgia, and North Carolina.

| LAB | LOCATION | TESTING |
|-------------------------------------|---|---|
| Chicago—Tempus Headquarters and Lab | 600 West Chicago Avenue Suite 510 Chicago, IL 60654 | <div><div>xT CDx</div> solid tumor + normal match 648 gene DNA sequencing panel</div> <div><div>xT</div> solid tumor only 648 gene DNA sequencing panel</div> <div><div>xR</div> whole transcriptome RNA sequencing panel</div> <div><div>xF/xF+</div> liquid biopsy 105/523 gene cfDNA sequencing panel</div> <div><div>xE</div> whole exome 19,000+ gene DNA sequencing panel</div> <div>Algorithmic Tests: IPS, TO, HRD, DPYD, UGT1A1, PurISTSM</div> <div>IHCs: MMR (MSH6, MSH2, MLH1, PMS2), PD-L1 (22C3, 28-8, SP142, SP263)</div> |
| Atlanta—Tempus Lab | 3100 Northwoods Place Peachtree Corners, GA 30071 | <div><div>nP</div> pharmacogenomic test covering 13 validated genes, approximately 90 variants, and 8 emerging evidence genes</div> |
| Durham—Tempus Lab | 25 Alexandria Way Suite 300 Durham, NC 27713 | <div><div>xM</div> tumor-naïve for minimal residual disease (MRD)</div> <div><div>xT</div> solid tumor + normal match 648 gene DNA sequencing panel</div> <div><div>xR</div> whole transcriptome RNA sequencing panel</div> <div><div>xF</div> liquid biopsy 105 gene cfDNA sequencing panel</div> <div>Algorithmic Tests: IPS, TO, HRD, DPYD, UGT1A1, PurISTSM</div> <div>IHCs: MMR (MSH6, MSH2, MLH1, PMS2), PD-L1 (22C3, 28-8, SP142, SP263)</div> |

xT CDx is a qualitative Next Generation Sequencing (NGS)-based in vitro diagnostic device intended for use in the detection of substitutions (single nucleotide variants (SNVs) and multi-nucleotide variants (MNVs)) and insertion and deletion alterations (INDELs) in 648 genes, as well as microsatellite instability (MSI) status, using DNA isolated from Formalin-Fixed Paraffin Embedded (FFPE) tumor tissue specimens, and DNA isolated from matched normal blood or saliva specimens, from previously diagnosed cancer patients with solid malignant neoplasms. The test is intended as a companion diagnostic (CDx) to identify patients who may benefit from treatment with the targeted therapies listed in the Companion Diagnostic Indications table in accordance with the approved therapeutic product labeling. Additionally, xT CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with previously diagnosed solid malignant neoplasms. Genomic findings other than those listed in the Companion Diagnostic Indications table are not prescriptive or conclusive for labeled use of any specific therapeutic product. xT CDx is a single-site assay performed at Tempus AI, Inc., Chicago, IL. For the complete xT CDx label, including companion diagnostic indications and important risk information, please visit tempus.com/xt-cdx-label/